Literature DB >> 32535805

A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli.

Taylor Morrisette1, Abdalhamid M Lagnf1, Sara Alosaimy1, Michael J Rybak2,3,4.   

Abstract

The use of daptomycin (DAP) in septic pulmonary emboli (SPE) remains controversial. We analyzed 29 cases of MRSA bacteremia complicated by SPE treated with DAP (n = 14) or DAP-ceftaroline fosamil (CPT; n = 15). Initial treatment with DAP monotherapy was found to have a success rate comparable with DAP-CPT (71% vs. 80%; p = 0.68).

Entities:  

Keywords:  Daptomycin; Methicillin-resistant Staphylococcus aureus; Septic pulmonary emboli

Mesh：

Substances：

Year:  2020        PMID： 32535805     DOI： 10.1007/s10096-020-03941-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  3 in total

Review 1.  Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by Staphylococcus aureus: A Comprehensive Review of the Evidence.

Authors:  Daniele Roberto Giacobbe; Silvia Dettori; Silvia Corcione; Antonio Vena; Chiara Sepulcri; Alberto Enrico Maraolo; Francesco Giuseppe De Rosa; Matteo Bassetti
Journal:  Infect Drug Resist       Date:  2022-04-22       Impact factor: 4.177

Review 2.  Comparing the Outcomes of Ceftaroline plus Vancomycin or Daptomycin Combination Therapy versus Vancomycin or Daptomycin Monotherapy in Adults with Methicillin-Resistant Staphylococcus aureus Bacteremia-A Meta-Analysis.

Authors:  Chienhsiu Huang; Ihung Chen; Lichen Lin
Journal:  Antibiotics (Basel)       Date:  2022-08-15

3.  Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study.

Authors:  Daniele Roberto Giacobbe; Chiara Russo; Veronica Martini; Silvia Dettori; Federica Briano; Michele Mirabella; Federica Portunato; Chiara Dentone; Sara Mora; Mauro Giacomini; Marco Berruti; Matteo Bassetti
Journal:  Antibiotics (Basel)       Date:  2021-06-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.